Millennium Management LLC Acquires New Position in Immunome, Inc. (NASDAQ:IMNM)

Millennium Management LLC acquired a new position in shares of Immunome, Inc. (NASDAQ:IMNM - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 158,428 shares of the company's stock, valued at approximately $1,683,000. Millennium Management LLC owned 0.20% of Immunome as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently bought and sold shares of IMNM. BNP Paribas Financial Markets purchased a new stake in shares of Immunome during the fourth quarter valued at $70,000. KLP Kapitalforvaltning AS purchased a new stake in shares of Immunome during the fourth quarter valued at $75,000. AlphaQuest LLC boosted its stake in shares of Immunome by 786,700.0% during the fourth quarter. AlphaQuest LLC now owns 7,868 shares of the company's stock valued at $84,000 after purchasing an additional 7,867 shares during the period. Tower Research Capital LLC TRC boosted its stake in shares of Immunome by 482.0% during the fourth quarter. Tower Research Capital LLC TRC now owns 8,608 shares of the company's stock valued at $91,000 after purchasing an additional 7,129 shares during the period. Finally, Aquatic Capital Management LLC purchased a new stake in shares of Immunome during the fourth quarter valued at $95,000. 44.58% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

IMNM has been the subject of a number of recent analyst reports. Wedbush reissued an "outperform" rating and set a $21.00 target price (down from $33.00) on shares of Immunome in a research note on Tuesday, May 13th. Guggenheim lowered their target price on shares of Immunome from $35.00 to $25.00 and set a "buy" rating for the company in a research note on Thursday, March 20th. Stephens restated an "overweight" rating and issued a $30.00 price objective on shares of Immunome in a report on Thursday, March 20th. Lake Street Capital assumed coverage on shares of Immunome in a report on Wednesday, April 2nd. They set a "buy" rating and a $23.00 target price on the stock. Finally, Lifesci Capital assumed coverage on shares of Immunome in a report on Tuesday, March 11th. They set an "outperform" rating and a $20.00 target price on the stock. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $23.33.

Insider Buying and Selling at Immunome

In other news, Director Jean Jacques Bienaime purchased 7,000 shares of the firm's stock in a transaction on Monday, March 24th. The stock was acquired at an average cost of $8.21 per share, with a total value of $57,470.00. Following the completion of the transaction, the director now owns 23,615 shares in the company, valued at $193,879.15. This represents a 42.13% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CTO Philip Tsai purchased 12,300 shares of the firm's stock in a transaction on Monday, March 24th. The shares were purchased at an average cost of $8.42 per share, with a total value of $103,566.00. Following the completion of the transaction, the chief technology officer now owns 33,300 shares of the company's stock, valued at approximately $280,386. The trade was a 58.57% increase in their position. The disclosure for this purchase can be found here. Over the last ninety days, insiders bought 161,400 shares of company stock valued at $1,207,395. 8.60% of the stock is currently owned by insiders.

Immunome Stock Performance

Immunome stock traded down $0.24 during midday trading on Wednesday, hitting $9.02. 937,342 shares of the company's stock were exchanged, compared to its average volume of 916,580. Immunome, Inc. has a 12 month low of $5.15 and a 12 month high of $16.81. The firm has a 50-day moving average of $7.73 and a two-hundred day moving average of $9.51. The company has a market cap of $784.85 million, a PE ratio of -1.11 and a beta of 1.94.

Immunome (NASDAQ:IMNM - Get Free Report) last released its quarterly earnings results on Monday, May 12th. The company reported ($0.52) EPS for the quarter, beating the consensus estimate of ($0.66) by $0.14. The business had revenue of $2.93 million during the quarter, compared to analyst estimates of $0.46 million. Immunome had a negative net margin of 3,014.59% and a negative return on equity of 48.63%. As a group, equities analysts expect that Immunome, Inc. will post -2.21 earnings per share for the current year.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.